Fig. 1.

Comparison of efficacy of first-line mild to moderate acne treatments in reducing total acne lesion count. BPO benzoyl peroxide. Clindamycin 1% + BPO 3% gel: Schaller et al. [20], Eichenfield et al. [21]; clindamycin 1% + BPO 5% gel BID: Langner et al. [30], Jackson et al. [38]; clindamycin 1% + tretinoin 0.025% lotion: Jackson et al. [38], NilFroushzadeh et al. [39]; clindamycin 1% + BPO 5% gel: Langner et al. [30]; clindamycin 1% lotion + adapalene 0.1% gel: Wolf et al. [40]. BPO 3% gel: Eichenfield et al. [28]; BPO 2.5% gel: Gollnick et al. [22], Babaeinejad and Fouladi [29]. Tretinoin 0.1% cream: Webster et al. [36]; tretinoin 0.025% gel: Cunliffe et al. [35], Webster [36]; tretinoin 0.025% cream: Webster [36]; tretinoin 0.1% gel: Webster et al. [36]; tretinoin 0.05% gel: Webster et al. [31], Tirado-Sánchez and Ponce-Olivera [33]; tretinoin 0.04% microsphere gel: Berger et al. [32]; adapalene 0.1% + BPO 2.5% combo gel: Gollnick et al. [22]; adapalene 0.3% gel: Thiboutot et al. [23], Pariser et al. [24], Tanghetti et al. [25], Tirado-Sánchez and Ponce-Olivera [33]; adapalene 0.1% lotion: Eichenfield et al. [28]; adapalene 0.1% gel: Gollnick et al. [22], Thiboutot et al. [23], Pariser et al. [24], Babaeinejad and Fouladi [29], Langner et al. [30], Tirado-Sánchez and Ponce-Olivera [33], Cunliffe et al. [35]; adapalene 0.1% cream: Shalita et al. [26], Lucky et al. [34]; tazarotene 1% cream: Tanghetti et al. [25], Shalita et al. [26]; tazarotene 1% foam: Feldman et al. [27]; tazarotene 0.1% gel: Shalita et al. [37]; tazarotene 0.05% gel: Shalita et al. [37]. Asterisk Treatment length varied from 12 weeks to 16 weeks. Double dagger symbol Treatment length varied from 8 to 12 weeks. Dagger symbol Treatment length varied from 12 weeks to 90 days